Business
CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the first quarter ended March 31, 2025 and provided clinical and corporate updates.
About this update from Calcimedica, Inc.
[{"type":"text","content":"Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025","length":145,"tagName":"p","attribs":{}},{"type":"text","content":"Presentations at three recent medical meetings, including a post-hoc analysis of subset of patients with AKI in the Phase 2 CARDEA trial of Auxora in severe COVID-19 pneumonia, which showed a 62.7% relative reduction in mortality for Auxora versus placebo","length":260,"tagName":"p","attribs":{}},{"type":"text","content":"Cash position expected to fund operations into mid-2026","length":55,"tagName":"p","attribs":{}},{"type":"text","content":"LA JOLLA, Calif., May 14, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the first quarter ended March 31, 2025 and provided clinical and corporate updates.","length":456,"tagName":"p"},{"type":"image","alt":"CalciMedica Logo (PRNewsfoto/CalciMedica, Inc.)","displaySize":"","headline":null,"caption":"CalciMedica Logo (PRNewsfoto/CalciMedica, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":78,"url":"https://media.zenfs.com/en/prnewswire.com/2555f332bbc6176084dcbe2b673b28ae"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/OrsqdcERGNiUdevuO33D2A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEzNztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/2555f332bbc6176084dcbe2b673b28ae","width":400,"height":78}},"href":"https://mma.prnewswire.com/media/685404/calcimedica_v3.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""We continue to execute across our pipeline and have taken steps to ensure that we are well-positioned ahead of multiple expected milestones in 2025," said Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica. "Our cash runway extends into mid-2026, which will allow us to deliver the readout of our Phase 2 KOURAGE trial in AKI with respiratory failure expected around the end of this year, as well as to discuss our Phase 3 program in acute pancreatitis with SIRS with the FDA. Our lead...